Solvay Pharmaceuticals

Solvay Pharmaceuticals have claimed 4,5-dihydro-l//-pyrazole derivatives in a series of patent applications [293-296], compounds (426 29) represent examples of the structures involved. 

A thiazole core has also been utilised by Solvay Pharmaceuticals [309] in the search for a novel bioisosterie replacement of the rimonabant (382) pyrazole core. The affinity of several compounds for the human CBi receptor was determined in transfected CHO cells using tritium-labelled CP 55940. Antagonism was determined in the same cell line by WIN 55212-2-induced release of arachidonic acid. The pK[ of (456) was found to be 6.9, while the p 2 value was measured as 8.7. A series of six 1,2,4-triazole analogues has been prepared by Jagerovic et al. [310], via their corresponding A-acylbenzamides (Table 6.39). 

Solvay Pharmaceuticals, Chemical and Pharmaceutical Development, C.J. van Houtenlaan 36, 1381 CP Weesp, The Netherlands... 

Lange, J., Kruse, C., Tipker, J., Tulp, M., van Vliet, B. (Solvay Pharmaceuticals) 4,5-Dihydro-1 H-pyrazole derivatives having CBrantagonistic activity, WO0170700 (2001). 

Solvay Engineered Polymers Pipelife Jet Stream Inc Solvay Pharmaceuticals Solvac... 

Manufacturers Axcan Pharma, Solvay Pharmaceuticals Inc., McNeil-PPC, Inc., Schwarz Pharma... 

Here are some actual observations made by the FDA during an inspection of a SAP R/3 application at Solvay Pharmaceuticals. The observations were made by Thomas Arista and Robert ToUefson... 

Bradley A. Clark / Solvay Pharmaceuticals, Inc., Marietta, Georgia, U.S.A. 

Very recently, Solvay Pharmaceuticals (Lange et al. 2004) reported a novel class of 3,4-disubstituted pyrazoline analogs exhibiting high CBi selectivity (e.g., 51, Fig. 12). Another novel class of CBi antagonists that has received only limited attention includes the 3-alkyl-5-arylhydantoins (Ooms et al. 2002). 

Luvox package insert. Solvay Pharmaceuticals, Marietta, GA, 2002. 

This work was supported in part by grants from the National Institute on Drug Abuse (DA 12605) and Solvay Pharmaceuticals, Inc. The author would hke to thank Professor R. Theobald for proofing and helpful suggestions and R. Chronister for typing the manuscript. 

Meristem Therapeutics Solvay Pharmaceuticals Gastric lipase Corn Phase II... 

Acknowledgments Our contributions in this field were supported by the Fonds der Chemis-chen Industrie. We thank G. Drager, G. Sourkouni-Argirusi, E. Kunst, S. Leue, F. Stuhlmann, W. Solodenko, and H. Wen for expert preparative contributions in the field of PASSflow technology. Furthermore, we thank Solvay Pharmaceuticals (Hannover, Germany), Bayer AG (Leverkusen, Germany), Aventis (Frankfurt), and Novabiochem (Switzerland) for financial and technical assistance. 

Mr. de Jong is currently ITQA manager and is responsible for the quality system of the IT department of Solvay Pharmaceuticals in The Netherlands. He started his career in IT in 1978 as system specialist for Honeywell Bull, and joined Solvay in 1985 as a system analyst for the R D (research and development) automation center, especially within the Good Laboratory Practice (GLP) environment. He was involved in the translation of GxP guidelines to the IT world, in system development as well as system management. He is also member of Solvay s Computer Validation Committee. 

Ms. Koelman is currently global GLP/GCP (Good Clinical Practice) QA director within Solvay Pharmaceuticals. Previously, she was head of the GLP Quality Assurance Unit of Solvay Pharmaceuticals. She has been the leader of the project team that set up the local computer validation policy of Solvay Pharmaceuticals B.V. and also leader of the team responsible for implementing this policy in the company over a period of two years, before it was handed over to a permanent Computer Validation Committee. She has been involved in a number of validation projects of different types of systems, ranging from simple equipment to complex custom-built or highly customized applications. 

---